The 4 most recent market catalysts affecting $MDWD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 65
MediWound Announces Additional $3.3M In Department Of War Funding To Develop Room-Temperature-Stable NexoBrid For Battlefield Burn Care
The additional $3.3M in funding is a positive corporate catalyst for MediWound, directly supporting the development of a room-temperature-stable NexoBrid. This could significantly …
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 85
MediWound Says DSMB Recommends Phase III VALUE Study Of EscharEx Continues Without Modification, No Safety Concerns Identified
The positive recommendation from the Data Safety Monitoring Board (DSMB) for MediWound's EscharEx Phase III VALUE study is a major de-risking event for the company. Clinical trial …
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 55
Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $30
Oppenheimer analyst Jeff Jones maintained an 'Outperform' rating on MediWound but lowered the price target from $32 to $30. This action signals a slight reduction in the analyst's …
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 75
MediWound Q2 EPS $(0.77) Misses $(0.76) Estimate, Sales $3.092M Beat $2.588M Estimate
MediWound's Q2 filing reveals a mixed financial performance. While the company managed to beat analyst sales estimates, the reported sales of $3.092 million represent a substantial…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.